Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jun 8 2018

Full Issue

AMA Poised To Vote On Whether Birth Control Should Be Sold Without A Prescription

There's been recent pressure on drugmakers to provide the contraception over the counter, and the physicians may be the latest to join in the movement. In other pharmaceutical news, another drugmaker has agreed to pay a penalty over its relationship with patient charities.

Stat: Pressure Mounts On Drug Makers To Move Birth Control Over The Counter

Drug makers are facing growing pressure to sell contraception without a prescription. And this weekend, the nation’s largest physicians group could join in the chorus calling to expand access to birth control. At the American Medical Association’s annual meeting in Chicago, delegates will vote on a resolution to encourage contraceptive makers to submit applications to the Food and Drug Administration to switch the status of their pills from prescription to over the counter. If it passes, the new policy would be directed more squarely at drug makers than the AMA’s current policy, which focuses on the FDA’s role. (Thielking, 6/8)

Stat: Lundbeck Will Pay $52 Million For Illegally Using A Charity To Assist Patients

Yet another drug maker has agreed in principle to pay a stiff fine to resolve an investigation into its relationships with patient charities. The latest company to do so is the U.S. subsidiary of Lundbeck (HLUYY), a Danish drug maker that will fork over $52.6 million. The announcement comes two years after the U.S. Attorney issued a subpoena in connection with an investigation of payments that Lundbeck made to an unspecified number of charities that provided financial assistance to patients taking various medicines. (Silverman, 6/7)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Tuesday, June 16
  • Monday, June 15
  • Friday, June 12
  • Thursday, June 11
  • Wednesday, June 10
  • Tuesday, June 9
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF